Tonix Pharmaceuticals (TNXP)
Commercializes TONMYA for fibromyalgia alongside branded acute migraine treatments.
Something off on this page? Send us feedback.
Markets TONMYA for fibromyalgia and branded acute migraine treatments, with sales concentrated in the United States. The business is shifting from development to commercialization while carrying CNS, infectious-disease, immunology, and rare-disease programs.
Markets TONMYA, an FDA-approved treatment for fibromyalgia in adults, alongside Zembrace SymTouch and Tosymra for acute migraine. Sales are concentrated in the United States, and the company reports through one operating segment.
Built around a long sublingual cyclobenzaprine development arc, the business now pairs commercial execution with a broad research agenda. Its platform includes sales, marketing, market access, distribution, patient support, and research programs across CNS, infectious disease, immunology, and rare disease.
Operating posture depends on TONMYA adoption and payer access after launch, continuing regulatory obligations for approved medicines, and progress across investigational programs outside the current marketed portfolio.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 10, 2026 | Raymond James | Reiterate | Rating: —Target: $26 | Target: $27 |
| Jun 24, 2026 | Raymond James | Initiate | Rating: —Target: — | Target: $26 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $176.2M · Total debt $1.3M · Total assets $254.1M · Shareholders' equity $222.3M
- Revenue
- $13.5M
- Operating income
- −$42.5M
- Net income
- −$40.6M
No dividends on record.
| Institutions | ≈ 59.07% | 9.42M shares | |
|---|---|---|---|
| 109 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.19% | 30.9K shares | |
| 7 holders · as of Sep 8, 2026 | |||
| Other | ≈ 40.74% | 6.49M shares | |
| remainder | |||
15.94M company shares as of Sep 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
2 positions filed across a stock split leave their adjustment unstated and stay out of the bar.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.77% | 1.40M | as of Jun 30, 2026 |
Sirenia Capital Management LPInstitution | 8.14% | 1.30M | filed May 15, 2026 |
Point72 Asset Management, L.P.Institution | 7.32% | 1.17M | as of Jun 30, 2026 |
Millennium Management LLCInstitution | 6.07% | 966,932 | as of Jun 30, 2026 |
AQR Capital Management LLCInstitution | 5.54% | 882,595 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 27, 2026 | Seth Lederman | director, officer: Chief Executive Officer | +2,000 | $13.79 |
| Aug 20, 2026 | Richard H. Bagger | director | +1,000 | $12.60 |
| Jun 12, 2026 | Carolyn E. Taylor | director | +1,415 | $10.55 |
| Jun 9, 2026 | Seth Lederman | director, officer: Chief Executive Officer | +5,000 | $11.79 |
| Jun 8, 2026 | Richard Newcomb Stillwell | director | +5,000 | $11.65 |
- AbbVie
Savella and Ubrelvy overlap across fibromyalgia and acute migraine
- Viatris
Lyrica anchors branded pregabalin overlap in fibromyalgia
- Eli Lilly
Cymbalta overlaps as an established SNRI fibromyalgia therapy
- Pfizer
Nurtec ODT and ZAVZPRET challenge branded acute migraine use
- Axsome Therapeutics
SYMBRAVO and AXS-14 add acute migraine and fibromyalgia pressure
- Teva (ADR)
Generic sumatriptan injection pressures Zembrace on price
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Tonix Pharmaceuticals | $10.12 | −4.44% | $168.8M | — | — | 5.8 | +577.9% |
| AbbVie | $264.77 | −0.16% | $468.77B | 74.8 | 17.4 | 7.3 | +10.2% |
| Viatris | $17.14 | −0.23% | $20.01B | — | 6.7 | 1.4 | +4.9% |
| Eli Lilly | $1,155.03 | −1.29% | $1.10T | 39.3 | 28.2 | 13.8 | +47.7% |
| Pfizer | $28.08 | +0.52% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Axsome Therapeutics | $195.64 | −3.67% | $10.45B | — | 1,167.3 | 13.5 | +44.2% |
| Teva (ADR) | $39.38 | −0.35% | $46.03B | 65.9 | 14.0 | 2.7 | −0.8% |
| Median | 52.6 | 15.7 | 5.0 | +7.5% |